The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Open accessAbstract
Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization. In total, 99 patients with clinical stage IIIb–d nodal melanoma were included and treated with 6 weeks of neoadjuvant ipilimumab 1 mg kg−1 and nivolumab 3 mg kg−1. In patients achieving major pathologic response (MPR, ≤10% viable tumor) in their index lymph node (ILN, the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted. Patients with pathologic partial response (pPR; >10 to ≤50% viable tumor) underwent TLND only, whereas patients with pathologic non-response (pNR; >50% viable tumor) underwent TLND and adjuvant systemic therapy ± synchronous radiotherapy. Primary objectives were confirmation of pRR (ILN, at week 6) of the winner neoadjuvant combination scheme identified in OpACIN-neo; to investigate whether TLND can be safely omitted in patients achieving MPR; and to investigate whether RFS at 24 months can be improved for patients achieving pNR. ILN resection and ILN-response-tailored treatment were feasible. The pRR was 72%, including 61% MPR. Grade 3–4 toxicity within the first 12 weeks was observed in 22 (22%) patients. TLND was omitted in 59 of 60 patients with MPR, resulting in significantly lower surgical morbidity and better quality of life. The 24-month relapse-free survival and distant metastasis-free survival rates were 93% and 98% in patients with MPR, 64% and 64% in patients with pPR, and 71% and 76% in patients with pNR, respectively. These findings provide a strong rationale for randomized clinical trials testing response-directed treatment personalization after neoadjuvant ipilimumab and nivolumab. Results from the PRADO extension cohort of the OpACIN-neo trial show that pathologic response rate to neoadjuvant ipilimumab and nivolumab can be used as a criterion for personalization of further treatment in stage III nodal melanoma, with the potential to reduce treatment morbidity and increase patient quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Self-citationNeoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Morton, D. L., Cochran, A. J., Thompson, J. F., Elashoff, R., Essner, R., Glass, E. C., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000181092.50141.fa · Cited by 715
Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0107 · Cited by 658
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationAscierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30494-0 · Cited by 537
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Self-citationGiesinger, J. M., Loth, F. L. C., Aaronson, N. K., Arraras, J. I., Caocci, G., Efficace, F., Groenvold, M., van Leeuwen, M., Petersen, M. A., Ramage, J., et al. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.10.003 · Cited by 373
Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01211-7 · Cited by 336
Self-citation
Cited by
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Self-citationNeoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, C. U., Lucas, M. W., Scolyer, R. A., van de Wiel, B. A., Menzies, A. M., Lopez-Yurda, M., Hoeijmakers, L. L., Saw, R. P. M., Lijnsvelt, J. M., Maher, N. G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402604 · Cited by 542
Self-citationTargeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Metadata
- Authors
- Reijers, I. L. M., Menzies, A. M., van Akkooi, A. C. J., Versluis, J. M., van den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., Rozeman, E. A., Klop, W. M. C., van Houdt, W. J., Sikorska, K., van der Hage, J. A., Grünhagen, D. J., Wouters, M. W., Witkamp, A. J., Zuur, C. L., Lijnsvelt, J. M., Torres Acosta, A., Grijpink-Ongering, L. G., Gonzalez, M., Jóźwiak, K., Bierman, C., Shannon, K. F., Ch’ng, S., Colebatch, A. J., Spillane, A. J., Haanen, J. B. A. G., Rawson, R. V., van de Wiel, B. A., van de Poll-Franse, L. V., Scolyer, R. A., Boekhout, A. H., Long, G. V., & Blank, C. U.
- Venue
- Nature Medicine
- Published
- 2022-06
- Volume
- 28
- Issue
- 6
- Pages
- 1178-1188
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4281783912
- Cited by
- 377
- References
- 35
- FWCI
- 26.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. https://app.cochat.ai/papers/10.1038/s41591-022-01851-x
- The paper
- Reijers, I. L. M., Menzies, A. M., van Akkooi, A. C. J., Versluis, J. M., van den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., Rozeman, E. A., Klop, W. M. C., van Houdt, W. J., Sikorska, K., van der Hage, J. A., Grünhagen, D. J., Wouters, M. W., Witkamp, A. J., . . . Blank, C. U. (2022). Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01851-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.